Combination therapy with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in heart failure patients with type 2 diabetes

Introduction Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve cardiovascular outcomes in type 2 diabetes (T2D), and SGLT2i reduces events in heart failure (HF). However, the benefit of their combination in patients with both conditi...

全面介紹

書目詳細資料

Principais autores:	Takao Kato, Takahiro Matsumoto, Takefumi Kishimori, Atsuyuki Wada, Akira Tani, Ryosuke Yamaji, Jumpei Koike, Yoshihiro Iwasaki, Takafumi Yagi, Masaharu Okada
格式:	Artigo
語言:	Inglês
出版:	BMJ Publishing Group 2025-11-01
叢編:	BMJ Open Diabetes Research & Care
在線閱讀:	https://drc.bmj.com/content/13/6/e005364.full
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!